Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

19.75 +1.73 (+9.60%)
Streaming Delayed Price Updated: 12:18 PM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Sarepta (SRPT) Q2 2026 Earnings Call Transcript ↗
Revenue fell 34% YoY as management narrows guidance and eyes 2027 growth. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Sarepta Therapeutics Q2 Earnings Call Highlights ↗
Sarepta Therapeutics (NASDAQ:SRPT) reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted... 
Via MarketBeat
Topics Earnings
Sarepta Therapeutics (NASDAQ:SRPT) Surges on Q2 Earnings Beat and Narrowed Outlook ↗
Via Chartmill
Topics Earnings
News headline image
2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
Your hard-earned money would be better spent elsewhere. 
Via The Motley Fool
Topics Artificial Intelligence
Sarepta Therapeutics (NASDAQ:SRPT) Q1 2026 Earnings Beat Overshadowed by Revenue Dip ↗
Via Chartmill
Topics Earnings
Sarepta Therapeutics (NASDAQ:SRPT) Posts Q4 Revenue Beat Amid Deep Losses and Major Charges ↗
Via Chartmill
News headline image
My Top 3 Biotech Stocks for May 2026 ↗
As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Sarepta (SRPT) Q1 2026 Earnings Transcript ↗
Sarepta (SRPT) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug... 
Via MarketMinute
Topics Intellectual Property Lawsuit
Why Did SRPT Stock Rise 6% In Pre-Market Today? ↗
Via Stocktwits
SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns ↗
Via Stocktwits
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular... 
Via MarketMinute
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years.... 
Via MarketMinute
News headline image
The RNA Renaissance: Decoding Sarepta Therapeutics’ 34% Surge and the Future of Precision Medicine
On March 25, 2026, the biotechnology sector witnessed a tectonic shift as Sarepta Therapeutics (NASDAQ: SRPT) saw its share price skyrocket by 34% in a single trading session. This dramatic surge—the... 
Via Finterra
Topics Retirement
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Wednesday's session: top gainers and losers ↗
Via Chartmill
Which stocks are gapping on Wednesday? ↗
Via Chartmill
News headline image
Sarepta Therapeutics (SRPT) at a Crossroads: A 2026 Deep Dive into the Future of Genetic Medicine
As of March 25, 2026, Sarepta Therapeutics (NASDAQ: SRPT) stands at a pivotal, albeit bruising, crossroads in the history of genetic medicine. Once the darling of the biotechnology sector for its... 
Via Finterra
Topics Economy Intellectual Property Retirement
News headline image
2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
These stocks aren't nearly as cheap as they look. 
Via The Motley Fool
Topics Cannabis
News headline image
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study ↗
Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy. 
Via Stocktwits
Topics Death
News headline image
Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗
Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged. 
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat ↗
A new Cohort 8 study aims to reopen the non-walking patient market with data expected by the end of 2026. 
Via Stocktwits
Topics Earnings
News headline image
Sarepta (SRPT) Q4 2025 Earnings Call Transcript ↗
Sarepta (SRPT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling ↗
Institutional support remains strong in February, with 134 investors increasing positions and 61 initiating new stakes. 
Via Stocktwits
Topics Intellectual Property
News headline image
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy ↗
While Sarepta’s gene therapy for the treatment of DMD called Elevidys was approved by the FDA in 2023, Regenxbio is developing its treatment. 
Via Stocktwits
Topics Intellectual Property Lawsuit
Which stocks are moving after the closing bell on Friday? ↗
Via Chartmill
News headline image
2 Beaten-Down Stocks That Could Sink Even More in 2026 ↗
Don't catch a falling knife. 
Via The Motley Fool
Topics Death
News headline image
Why Is SRPT Stock Falling Today? ↗
Sarepta Therapeutics announced a debt refinancing plan totaling about $291 million. 
Via Stocktwits
News headline image
Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears
New York, NY – December 9, 2025 – Dyne Therapeutics (NASDAQ: DYN) found itself in an unusual spotlight today, emerging as a significant market mover, albeit in a direction that belied ostensibly... 
Via MarketMinute
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.